HIV CLINICAL TRIALS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

HIV Clinical Trials Market, By Phase (Phase I, Phase II, Phase III, Phase IV, and Preclinical), By Study Design (Interventional Studies, Observational Studies, and Expanded Access Studies), By Sponsor Type (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, Government & Private Research Organizations, and Contract Research Organizations (CROs)), By Indication (HIV-1 and HIV-2), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In October 2024, Gilead Sciences, a biopharmaceutical company, and Merck, a global healthcare company, announced Phase 2 data on October 19, 2024, showing that a once-weekly oral combination of islatravir and lenacapavir maintained viral suppression in HIV-1 patients for 48 weeks. The investigational regimen achieved a 94.2% viral suppression rate, with no participants experiencing a viral load above 50 copies/mL. This novel combination, advancing to Phase 3, could become the first weekly oral HIV treatment, offering a new option in personalized HIV care.
In July 2024, Gilead Sciences, a biopharmaceutical company, launched two clinical trials to assess the effectiveness of lenacapavir, a long-acting HIV prevention injection, in underrepresented populations, including cisgender women and people who inject drugs. The trials, part of the HIV Prevention Trials Network (HPTN), aim to evaluate the safety, acceptability, and pharmacokinetics of the drug, which is already FDA-approved for HIV treatment. The studies will provide crucial data on how these populations respond to the treatment, helping improve HIV prevention strategies.
In July 2024, ViiV Healthcare, a global leader in HIV treatment, announced positive results from the PASO DOBLE study, the largest Phase IV clinical trial comparing the 2-drug regimen Dovato (dolutegravir/lamivudine) with the 3-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) for maintenance therapy in HIV-1 patients